BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-967@pharmaconomics
DTSTAMP:20260707T034748Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ENGN PDUFA — detalimogene voraplasmid (estimated date)
DESCRIPTION:The FDA's approval decision on detalimogene voraplasmid for high-risk\, non-muscle invasive bladder cancer (NMIBC) is due ~ Dec 31\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/engn-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/967
URL:https://www.pharmaconomics.com/e/967
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ENGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR